Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Chinese Adults with AQP4-positive NMOSD
ChiCTR2600129539Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Huashan Hospital. Primary endpoint: Adjudicated on-trial annualized relapse rate (ARR). Started Aug 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2600129539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129539.